Wire · operational-macro
Follow the money: The MedTech maths
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
Australia offers a compelling economic advantage for early-stage MedTech clinical studies due to its favourable exchange rate, a refundable R&D Tax Incentive effectively reducing costs by up to 43.5%, and a regulatory process that accelerates time to patient recruitment and evidence generation compared to Europe.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
You can nearly quarter your clinical study costs and speed up evidence generation by starting trials in Australia rather than Europe. Founders in MedTech should explore APAC early-stage clinical pathways to maximise runway and reduce dilution now.
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics